Table 2.
Clinical trials of CAR-Treg, CAR-γδT, CAR-NKT, CAR-NK, CAR-M and iCARs
| NCT | Cell source | Target | Cancer | Phase | Status | Location | |
|---|---|---|---|---|---|---|---|
| Treg [3] | NCT05114837 | Treg | CD19 | ALL | I/II | Not yet recruiting | US |
| NCT04817774 | Treg | HLA-A2 | Renal Transplant Rejection | I/II | Recruiting | Europe | |
| NCT05234190 | Treg | HLA-A2 | Liver Transplant Rejection | I/II | Recruiting | UK | |
| γδT cells [7] | NCT02656147 | γδT | CD19 | B-cell Lymphoma, ALL, CLL | I | Unknown | China |
| NCT05554939 | γδT | CD19 | NHL | I/II | Recruiting | China | |
| NCT04735471 | γδT | CD20 | B-cell Malignancies | I | Recruiting | US | |
| NCT04702841 | γδT | CD7 | T-cell Malignancies | Early I | Recruiting | China | |
| NCT05388305 | γδT | CD123 | AML | NA | Recruiting | China | |
| NCT04796441 | γδT | CD123 | AML | NA | Recruiting | China | |
| NCT04107142 | γδT | NKG2DL | Solid Tumors | I | Unknown | Malaysia | |
| NKT cells [5] | NCT05487651 | NKT | CD19 | B-cell Malignancies | I | Recruiting | US |
| NCT03774654 | NKT | CD19 | B-cell Malignancies | I | Recruiting | US | |
| NCT00840853 | NKT | CD19 | ALL, NHL | I | Active, Not recruiting | US | |
| NCT04814004 | NKT | CD19 | B-cell Malignancies | I | Recruiting | China | |
| NCT03294954 | NKT | GD2 | Neuroblastoma | I | Active, Not recruiting | US | |
| NK cells [48] | NCT00995137 | PB NK | CD19 | ALL | I | Completed | US |
| NCT05020678 | PB NK | CD19 | B-cell Malignancies | I | Recruiting | US | |
| NCT03824964 | PB NK | CD19/22 | B-cell Lymphoma | Early I | Unknown | Unknown | |
| NCT03692767 | PB NK | CD22 | B-cell Lymphoma | Early I | Unknown | Unknown | |
| NCT04623944 | PB NK | NKG2DL | AML, MDS | I | Recruiting | US | |
| NCT03415100 | PB NK | NKG2DL | Metastatic Solid Tumors | I | Unknown | China | |
| NCT03692637 | PB NK | Mesothelin | Epithelial Ovarian Cancer | Early I | Unknown | Unknown | |
| NCT02944162 | NK-92 | CD33 | AML | I/II | Unknown | China | |
| NCT02742727 | NK-92 | CD7 | Leukemia, Lymphoma | I/II | Unknown | China | |
| NCT02892695 | NK-92 | CD19 | Leukemia, Lymphoma | I/II | Unknown | China | |
| NK cells [48] | NCT03690310 | NK-92 | CD19 | B-cell Lymphoma | Early I | Unknown | Unknown |
| NCT03692663 | NK-92 | PSMA | Prostate Cancer | Early I | Recruiting | China | |
| NCT03940833 | NK-92 | BCMA | MM | I/II | Unknown | China | |
| NCT02839954 | NK-92 | MUC1 | Solid Tumors | I/II | Unknown | China | |
| NCT03940820 | NK-92 | ROBO1 | Solid Tumors | I/II | Unknown | China | |
| NCT03931720 | NK-92 | ROBO1 | Malignant Tumor | I/II | Unknown | China | |
| NCT03941457 | NK-92 | ROBO1 | Pancreatic Cancer | I/II | Unknown | China | |
| NCT05528341 | NK-92 | NKG2DL | Solid Tumors | I | Recruiting | China | |
| NCT03383978 | NK-92 | HER2 | Glioblastoma | I | Recruiting | Germany | |
| NCT03656705 | NK-92 | PD-L1 | Advanced NSCLC | I | Recruiting | China | |
| NCT04050709 | NK-92 | PD-L1 | Advanced Solid Cancers | I | Active, Not recruiting | US | |
| NCT04847466 | NK-92 | PD-L1 | GEJ Cancers, HNSCC | II | Recruiting | US | |
| NCT04796675 | CB NK | CD19 | B-Lymphoid Malignancies | I | Recruiting | China | |
| NCT03056339 | CB NK | CD19 | B-Lymphoid Malignancies | I/II | Active, Not recruiting | US | |
| NCT05472558 | CB NK | CD19 | NHL | I | Recruiting | China | |
| NCT05667155 | CB NK | CD19/CD70 | NHL | I | Not yet recruiting | China | |
| NCT05092451 | CB NK | CD70 | AML, MDS, B-cell Lymphoma | I/II | Recruiting | US | |
| NCT05110742 | CB NK | CD5 | Hematological Malignances | I/II | Not yet recruiting | US | |
| NCT05008536 | CB NK | BCMA | MM | Early I | Recruiting | China | |
| NCT05673447 | Unknown | CD19 | DLBCL | Early I | Not yet recruiting | Unknown | |
| NCT05645601 | Unknown | CD19 | B-cell Malignancies | I | Recruiting | China | |
| NCT04639739 | Unknown | CD19 | NHL | Early I | Not yet recruiting | China | |
| NCT04887012 | Unknown | CD19 | NHL | I | Recruiting | China | |
| NCT05654038 | Unknown | CD19 | B-cell Malignancies | I/II | Recruiting | China | |
| NCT05410041 | Unknown | CD19 | B-cell Malignancies | I | Recruiting | China | |
| NK cells [48] | NCT05336409 | Unknown | CD19 | B-cell Malignancies | I | Recruiting | US |
| NCT05563545 | Unknown | CD19 | ALL | I | Completed | China | |
| NCT04796688 | Unknown | CD19 | B-cell Malignancies | I | Recruiting | China | |
| NCT05652530 | Unknown | BCMA | MM | Early I | Recruiting | China | |
| NCT05008575 | Unknown | CD33 | AML | I | Recruiting | China | |
| NCT05215015 | Unknown | CD33/CLL1 | AML | Early I | Recruiting | China | |
| NCT05574608 | Unknown | CD123 | AML | Early I | Recruiting | China | |
| NCT05247957 | Unknown | NKG2DL | AML | NA | Terminated | China | |
| NCT05213195 | Unknown | NKG2DL | Metastatic Colorectal Cancer | I | Recruiting | China | |
| NCT05507593 | Unknown | DLL3 | SCLC | I | Recruiting | China | |
| NCT05410717 | Unknown | CLDN6 | Advanced Solid Tumors | I/II | Recruiting | China | |
| NCT05137275 | Unknown | 5T4 | Advanced Solid Cancers | Early I | Recruiting | China | |
| NCT05194709 | Unknown | 5T4 | Advanced Solid Tumors | Early I | Recruiting | China | |
| Macrophages [1] | NCT04660929 | Macrophages | HER2 | Solid Tumors | I | Recruiting | US |
| iPSCS [5] | NCT04629729 | FT819 | CD19 | B-cell Lymphoma, ALL, CLL | I | Recruiting | US |
| NCT05182073 | FT576 | BCMA | MM | I | Recruiting | US | |
| NCT04245722 | FT596 | CD19 | B-cell Lymphoma, CLL | I | Recruiting | US | |
| NCT04555811 | FT596 | CD19 | NHL, DLBCL, B-cell Lymphoma | I | Recruiting | US | |
| NCT03824951 | iPSCs | CD19 | B-cell Lymphoma | Early I | Unknown | Unknown |
AML Acute Myeloid Leukemia, CLL Chronic Lymphocytic Leukemia, NHL Non-Hodgkin lymphoma, MM Multiple Myeloma, AML Acute Myeloid Leukemia, MDS Myelodysplastic Syndromes, NSCLC Non-Small Cell Lung Cancer, GEJ Gastric and Gastroesophageal Junction, HNSCCs Head and Neck Squamous Cell Carcinomas, DLBCL Diffuse large B-cell lymphoma, SCLC Small Cell Lung Cancer